This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
For patients who are candidates for renal transplantation (RT), major surgeries such as coronary artery bypass grafting (CABG) are associated with cardiac complications as well as higher rates of post-operative complications, including the need for large amounts of blood transfusion, worsening kidney function, infection, and graft rejection.
Lung transplantation has become the definitive treatment for end stage respiratory disease. Numbers and survival rates have increased over the past decade, with transplant recipients living longer and with gre.
Patients can develop de novo malignancies following orthotopic heart transplantation. However, vascular tumors are not commonly described in this population.
Lung transplantation is one of the most common treatment options for patients with end-stage chronic obstructive pulmonary disease. However, the choice between single and double lung transplantation for these.
Background The treatment of pulmonary hypertension (PH) has improved rapidly in recent decades. Treatment escalation was defined as an additional pulmonary arterial hypertension (PAH) drug, pulmonary endarterectomy, percutaneous balloon angioplasty or bilateral lung transplantation.
Atrial tachycardia (AT) involving the surgical cuff between the donor pulmonary veins (dPV) and recipient left atrium (rLA) following lung transplantation (LT) typically occurs in the late postoperative period.
BackgroundLung transplantation (LTx) is the definitive treatment for end-stage pulmonary diseases, with venoarterial extracorporeal membrane oxygenation (VA-ECMO) used as a common perioperative support. Patients were divided into central (n=31) and peripheral (n=91) groups.
Pulmonary hernia is a rare condition characterized by the protrusion of lung tissue through a chest wall defect. Trauma and thoracic surgery are the most common causes of acquired lung hernias. We present an u.
BACKGROUND:The infiltration of macrophages into the lungs is a common characteristic of perivascular inflammation, contributing to vascular remodeling in pulmonary hypertension (PH). Peli1-deficient mice and bone marrow transplant mice were utilized to explore the roles of Peli1 in macrophages in vivo. Hypertension, Ahead of Print.
Patients with significant pulmonary oedema or aortic valve (AV) closure during venoarterial extracorporeal membrane oxygenation (VA-ECMO) were randomized to early left ventricular (LV) unloading or conventional strategy groups (1:1). CV, cardiovascular; HT, heart transplantation; ICU, intensive care unit; LVAD, left ventricular assist device.
Methods We studied 3 CMP CF patients referred for heart-lung transplantation and a prospective series of 120 adult CF patients. Histopathological study was performed on hearts obtained in transplant or necropsy. Cardiac magnetic resonance imaging (CMR) was performed in patients with CMP and in a control group.
Background:Neonates with complex congenital heart disease and pulmonary overcirculation have been historically treated surgically. Pulmonary arteries grew adequately for age, and devices were easily removed without complications. Circulation: Cardiovascular Interventions, Ahead of Print. At a median follow-up of 6.2 months (IQR, 4.0–10.8),
BackgroundThe modified Blalock‐Taussig‐Thomas shunt is the gold standard palliation for securing pulmonary blood flow in infants with ductal‐dependent pulmonary blood flow. Intervention was not significantly associated with odds of 30‐day transplant‐free survival (OR,1.18 [95% CI, 0.70–1.99])
ECMO can serve as a bridge to transplant in a chronic setting or as a salvage therapy for patients who are unable to be weaned from bypass following cardiac surgery. This technique resulted in a VV-VA or VPa-VA configuration, as oxygenated blood was being returned to the pulmonary artery as well as the descending aorta.
Background Pulmonary hypertension (PH) is a common complication in patients with complete dextro-transposition of the great arteries (TGA) after atrial switch (D-TGA/AS) and congenitally corrected TGA (ccTGA). In follow-up (median 23 months), HFHs/year were similar to the year prior to IHM (median 0 (IQR 0–1.0) before vs 0 (0–0.8)
UA level was associated to pulmonary capillary wedge pressure (PCWP) and cardiac index (CI) in univariable (both p<0.001) and multivariable regression analysis (p<0.004 and p=0.025 for PCWP and CI). Median UA was 0.48 (0.39–0.61) mmol/L.
PVI, pulmonary vein isolation. Abstract Aims The CASTLE-HTx trial showed the benefit of atrial fibrillation (AF) ablation compared to medical therapy in decreasing mortality, need for left ventricular assist device implantation or heart transplantation (HTx) in patients with end-stage heart failure (HF).
This new population was referred to as arterial-lymphatic-like ECs according to its cellular markers, and its appearance was validated in the pulmonary small arteries afterAlk1deletion. Transplantation of these cells caused vascular malformations.
Introduction: Wellnest brings you , the latest medical news where an infant successfully received a partial heart transplant! In a remarkable leap forward for pediatric cardiac care, a groundbreaking partial heart transplant procedure has emerged as a beacon of hope for infants facing severe congenital heart conditions.
Objective Pulmonary arterial hypertension (PAH), caused by pulmonary artery remodelling and increased pulmonary vascular resistance (PVR) due to an unknown mechanism, is an intractable disease with a poor prognosis. The primary outcome was death or lung transplantation.
Chronic Pulmonary Disease Lung diseases like chronic obstructive pulmonary disease (COPD) can lead to pulmonary hypertension, which in turn can cause the right side of the heart to enlarge, a condition known as cor pulmonale. Heart Transplant may be considered in severe cases where other treatments have failed.
Among adults with pulmonary arterial hypertension at high risk for death, sotatercept reduced the risk of a composite of death from any cause, lung transplantation, or hospitalization for worsening pulmonary arterial hypertension.
Objective A 45% threshold of right ventricular ejection fraction (RVEF) is proposed clinically relevant in patients with pulmonary arterial hypertension (PAH). We aim to determine treatment response, long-term right ventricular (RV) functional stability and prognosis of patients with PAH reaching or maintaining the RVEF 45% threshold.
BACKGROUND:Right ventricular-arterial coupling (RVAC) describes the relationship between right ventricular contractility and pulmonary vascular afterload. In a retrospective analysis, hybrid (echo and invasive) RVAC metrics included TAPSE/pulmonary vascular resistance (PVRi) and RVFW-LS/PVRi.
Food and Drug Administration ( FDA ) of the company's Cordella Pulmonary Artery (PA) Sensor System for the treatment of New York Heart Failure (NYHA) class III heart failure patients. milla1cf Mon, 06/24/2024 - 20:21 June 24, 2024 — Endotronix, Inc. ,
API strongly correlated with the left ventricular coupling ratio ( R 2 = 0.81) and the strength of association became even stronger under loaded conditions where pulmonary capillary wedge pressure (PCWP) was >20 mmHg ( R 2 = 0.94). Results Approximately 1010 discrete heart failure scenarios were modeled.
Getty Images milla1cf Wed, 03/13/2024 - 16:49 March 13, 2024 — BioCardia, Inc. , The study includes an eligibility requirement that patients demonstrate a pre-specified NT-proBNP level at baseline.
The primary effectiveness endpoint was a composite of death, heart transplant/left ventricular assist device (LVAD) implantation, HF hospitalization, outpatient HF worsening, and quality of life. This causes pulmonary congestion and makes it hard to breathe during activities or even at rest. HF affects 7 million people in the U.S,
Background:Patients with Fontan palliation have reduced aerobic capacity because of impaired cardiac, pulmonary, and skeletal muscle function. We assessed the correlates of predicted peak VO2, and the relationship between predicted peak VO2quartiles and cardiovascular outcomes (death/transplant).Results:Of 15.2 - 23.9)
CV mortality is the composite endpoint for CV mortality + urgent transplant + left ventricular assist device implantation. The primary endpoint of the study was the composite of cardiovascular death, left ventricular assist device implantation, and urgent heart transplantation. Events per 1000 person-years. #
n=42; median RAP, 4 mm Hg; pulmonary capillary wedge pressure, 11 mm Hg), those with a low JV distensibility ratio (≤1.6; was identified as the most accurate to discriminate between patients with RAP ≤7 versus >7 mm Hg (area under the receiver operating characteristic curve, 0.74 [95% CI, 0.64–0.84]) versus 18.2%; log-rankP=0.034).CONCLUSIONS:Ultrasound-assessed
CT angiogram chest: no aortic dissection or pulmonary embolism. Serial chest xrays: progressive bilateral pulmonary edema. The last information available is that the patient was undergoing heart transplant evaluation. She died before she could get a heart transplant. No further troponins were measured.
CXR confirmed bilateral pulmonary edema and bilateral small effusions. Her labs were remarkable for slight transaminitis without hyperbilirubinemia, elevated BNP (1,226 mg/dL), and elevated troponin (73 ng/L), all of which seemed reasonably attributable to the possible 48 hours of ventricular tachycardia, congestive hepatopathy, etc.
Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori 1 Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion 2 Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The (..)
Stunning topline results from Merck Winrevair’s Phase 3 ZENITH trial found that the drug significantly reduced morbidity and mortality risks in patients with pulmonary arterial hypertension, paving the way for stronger commercialization and further functional trials. Adverse events weren’t serious, but headache (24.5%
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
52 
Let's personalize your content